HUE053296T2 - TFR-elleni antitestek és alkalmazásuk proliferatív és gyulladásos rendellenességek kezelése során - Google Patents
TFR-elleni antitestek és alkalmazásuk proliferatív és gyulladásos rendellenességek kezelése soránInfo
- Publication number
- HUE053296T2 HUE053296T2 HUE16744353A HUE16744353A HUE053296T2 HU E053296 T2 HUE053296 T2 HU E053296T2 HU E16744353 A HUE16744353 A HU E16744353A HU E16744353 A HUE16744353 A HU E16744353A HU E053296 T2 HUE053296 T2 HU E053296T2
- Authority
- HU
- Hungary
- Prior art keywords
- proliferative
- treatment
- inflammatory disorders
- tfr antibodies
- tfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306192 | 2015-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE053296T2 true HUE053296T2 (hu) | 2021-06-28 |
Family
ID=53776520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16744353A HUE053296T2 (hu) | 2015-07-22 | 2016-07-21 | TFR-elleni antitestek és alkalmazásuk proliferatív és gyulladásos rendellenességek kezelése során |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11230605B2 (enExample) |
| EP (1) | EP3325509B1 (enExample) |
| JP (1) | JP6858185B2 (enExample) |
| KR (1) | KR102690998B1 (enExample) |
| CN (1) | CN107849136B (enExample) |
| AU (1) | AU2016296321B2 (enExample) |
| CA (1) | CA2992509C (enExample) |
| CY (1) | CY1123941T1 (enExample) |
| DK (1) | DK3325509T3 (enExample) |
| ES (1) | ES2860988T3 (enExample) |
| HR (1) | HRP20210393T1 (enExample) |
| HU (1) | HUE053296T2 (enExample) |
| IL (1) | IL257065B (enExample) |
| LT (1) | LT3325509T (enExample) |
| MX (1) | MX2018000569A (enExample) |
| PL (1) | PL3325509T3 (enExample) |
| PT (1) | PT3325509T (enExample) |
| RS (1) | RS61586B1 (enExample) |
| RU (1) | RU2737637C2 (enExample) |
| SI (1) | SI3325509T1 (enExample) |
| SM (1) | SMT202100134T1 (enExample) |
| WO (1) | WO2017013230A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179817B2 (en) | 2015-05-04 | 2019-01-15 | Cytomx Therapeutics, Inc. | Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof |
| FR3062213B1 (fr) | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| CN112955153A (zh) | 2018-08-02 | 2021-06-11 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN112912499A (zh) | 2018-08-02 | 2021-06-04 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP4069745A4 (en) * | 2019-11-06 | 2024-05-29 | The Regents Of The University Of California | Compositions and methods for transferrin receptor 1 targeting |
| IL295022A (en) * | 2020-01-31 | 2022-09-01 | Dyne Therapeutics Inc | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| MX2024002753A (es) | 2021-09-01 | 2024-05-20 | Biogen Ma Inc | Anticuerpos anti receptor de transferrina y usos de los mismos. |
| US20240376222A1 (en) * | 2021-09-13 | 2024-11-14 | The Board Of Regents Of The University Of Texas System | Tfr antigen binding proteins and uses thereof |
| CN119183457A (zh) | 2022-04-15 | 2024-12-24 | 达因疗法公司 | 用于治疗强直性肌营养不良的肌肉靶向复合物和制剂 |
| EP4626923A1 (en) * | 2022-12-02 | 2025-10-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-tfr1 antibodies and uses thereof |
| TW202444759A (zh) | 2023-03-24 | 2024-11-16 | 美商戴納立製藥公司 | Ａβ靶向蛋白及使用方法 |
| EP4477236A1 (en) | 2023-06-14 | 2024-12-18 | Inatherys | Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics |
| WO2025090898A1 (en) * | 2023-10-26 | 2025-05-01 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof cross reference to related applications |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434156A (en) | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
| HUP0104865A3 (en) * | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| WO2005011082A2 (en) | 2003-07-23 | 2005-02-03 | Univeral Infusion Technology | Drive motor transmission system |
| ES2379526T3 (es) * | 2004-04-30 | 2012-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticuerpo anti-TfR |
| KR101295139B1 (ko) * | 2004-06-07 | 2013-08-12 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | 트랜스페린 리셉터 항체 |
| JP4361545B2 (ja) * | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| FR2953841B1 (fr) | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| US20150197574A1 (en) * | 2012-08-02 | 2015-07-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of transferrin receptor antagonist for the treatment of thalassemia |
| CN104797600A (zh) * | 2012-11-08 | 2015-07-22 | 国立大学法人宫崎大学 | 能够特异性识别转铁蛋白受体的抗体 |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
-
2016
- 2016-07-21 SI SI201631117T patent/SI3325509T1/sl unknown
- 2016-07-21 DK DK16744353.0T patent/DK3325509T3/da active
- 2016-07-21 EP EP16744353.0A patent/EP3325509B1/en active Active
- 2016-07-21 KR KR1020187004745A patent/KR102690998B1/ko active Active
- 2016-07-21 PT PT167443530T patent/PT3325509T/pt unknown
- 2016-07-21 AU AU2016296321A patent/AU2016296321B2/en active Active
- 2016-07-21 ES ES16744353T patent/ES2860988T3/es active Active
- 2016-07-21 HU HUE16744353A patent/HUE053296T2/hu unknown
- 2016-07-21 WO PCT/EP2016/067465 patent/WO2017013230A1/en not_active Ceased
- 2016-07-21 CN CN201680040714.2A patent/CN107849136B/zh active Active
- 2016-07-21 CA CA2992509A patent/CA2992509C/en active Active
- 2016-07-21 MX MX2018000569A patent/MX2018000569A/es unknown
- 2016-07-21 US US15/746,590 patent/US11230605B2/en active Active
- 2016-07-21 JP JP2018522867A patent/JP6858185B2/ja active Active
- 2016-07-21 RS RS20210280A patent/RS61586B1/sr unknown
- 2016-07-21 LT LTEP16744353.0T patent/LT3325509T/lt unknown
- 2016-07-21 SM SM20210134T patent/SMT202100134T1/it unknown
- 2016-07-21 PL PL16744353T patent/PL3325509T3/pl unknown
- 2016-07-21 IL IL257065A patent/IL257065B/en unknown
- 2016-07-21 HR HRP20210393TT patent/HRP20210393T1/hr unknown
- 2016-07-21 RU RU2018106364A patent/RU2737637C2/ru active
-
2021
- 2021-03-09 CY CY20211100200T patent/CY1123941T1/el unknown
- 2021-12-09 US US17/546,208 patent/US12037408B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE053296T2 (hu) | TFR-elleni antitestek és alkalmazásuk proliferatív és gyulladásos rendellenességek kezelése során | |
| IL279752A (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| IL262092A (en) | Humanized anti-pacap antibodies and uses thereof | |
| IL256687B (en) | Isolated tau-binding antibody and its use in treatment and diagnosis | |
| HUE052771T2 (hu) | C10orf54 elleni antitestek és alkalmazásuk | |
| HUE048284T2 (hu) | Anti-CD40 antitestek és alkalmazásuk | |
| SI3240554T1 (sl) | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| HUE046756T2 (hu) | Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei | |
| HUE058755T2 (hu) | Anti-tigit antigénkötõ proteinek és felhasználásuk módszerei | |
| HUE062189T2 (hu) | Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére | |
| HUE052095T2 (hu) | Keratin kezelési készítmények és eljárások | |
| HUE061253T2 (hu) | Antitestek OX40 ellen és azok felhasználásai | |
| SMT202400477T1 (it) | Anticorpi tetravalenti bispecifici e loro procedimenti di fabbricazione e d'uso | |
| HUE061576T2 (hu) | Kevert allergén készítmények és eljárások alkalmazásukra | |
| BR112016021626A2 (pt) | indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas | |
| PT2953969T (pt) | Anticorpos anti-il-17a e utilização dos mesmos no tratamento de distúrbios autoimunes e inflamatórios | |
| PL3481846T3 (pl) | 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA | |
| LT3532499T (lt) | Antikūnai prieš il-33 ir jų panaudojimas | |
| HUE036084T2 (hu) | Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél | |
| HUE052223T2 (hu) | IGF-1R ellenanyag és alkalmazása rák kezelésében célzóeszközként | |
| HUE046749T2 (hu) | Antigénreceptorok és azok felhasználása | |
| HUE054093T2 (hu) | Anti-HtrA1 antitestek és azok alkalmazási eljárásai | |
| HUE055020T2 (hu) | Prosztata-antigén szabványok és azok felhasználása |